KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - Other
Ratios

Bristol Myers Squibb (BMY) EBIAT (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed EBIAT for 17 consecutive years, with $3.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, EBIAT rose 102.4% to $3.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $7.1 billion, a 178.84% increase, with the full-year FY2025 number at $7.1 billion, up 178.84% from a year prior.
  • EBIAT was $3.5 billion for Q4 2025 at Bristol Myers Squibb, up from $2.2 billion in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $6.3 billion in Q3 2023 to a low of -$11.9 billion in Q1 2024.
  • A 5-year average of $974.3 million and a median of $1.4 billion in 2022 define the central range for EBIAT.
  • Peak YoY movement for EBIAT: tumbled 238320.0% in 2024, then skyrocketed 32650.0% in 2025.
  • Bristol Myers Squibb's EBIAT stood at $4.4 billion in 2021, then crashed by 53.65% to $2.0 billion in 2022, then dropped by 12.89% to $1.8 billion in 2023, then dropped by 1.63% to $1.7 billion in 2024, then surged by 102.4% to $3.5 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's EBIAT are $3.5 billion (Q4 2025), $2.2 billion (Q3 2025), and $1.3 billion (Q2 2025).